Items tagged with Drug-resistant TB
South Africa ensures reduction of prices for bedaquiline to benefit the world (post)
The cost of bedaquiline drops to 400 USD/6-month treatment course, effective immediately and will be made available for all TB programs procuring from the Stop TB Partnership’s Global Drug Facility (GDF).
Union working group show crucial link between TB and mental health (post)
The Union’s TB and Mental Health Working Group have released a video, Learning from the field: the mental health management of MDR-TB in Peru, to promote the wide-scale provision of mental health screening and services for patients receiving treatment for tuberculosis (TB) worldwide.
Union position on injectable-free regimens for the treatment of drug-resistant TB (post)
South Africa recently announced it would be providing all oral-regimens to a majority of persons with rifampicin-resistant tuberculosis (RR-TB)[1] by replacing injectable medicines with bedaquiline. This decision was based on a retrospective cohort analysis from the country showing improved treatment success and reduction of mortality when bedaquiline was given to persons with drug resistant-TB (DR-TB) under programmatic conditions (https://www.thelancet.com/journals/lanres/onlineFirst).
New TB drugs are safe, effective alternatives (post)
New interim findings from endTB indicate bedaquiline and delamanid could benefit many more patients.
A pan-TB regimen: The debate continues (post)
Multidrug-resistant tuberculosis (MDR-TB) treatment is evolving. Last month the South Africa National Tuberculosis Program decided to prioritize oral bedaqualine for all rifampin-resistant TB (RR-TB) in place of — the often more toxic — injectable drugs. The question of whether a package of novel oral medications as part of a universal regimen can replace the current approach to TB management divides the TB therapeutic community. In this second article we further explore this divergence of opinion.
Webinar: Implementing a bedaquiline-based, injectable-free regimen for drug-resistant TB (post)
Treatment Action Group (TAG), the Global TB Community Advisory Board (TB CAB) and the Drug-Resistant TB Treatment Scale-up Action Team (DR-TB STAT) will host a webinar on 16 August 2018 at 10 am EDT / 4 pm South Africa / 5 pm Kenya on implementing a bedaquiline-based, injectable-free regimen for drug-resistant TB (DR-TB) in light of the new World Health Organization (WHO) policy brief on DR-TB regimens.
South Africa strikes deal on new TB drug as WHO revisits guidance (post)
AMSTERDAM — The World Health Organization could soon start promoting a new tuberculosis drug that is now more affordable after South Africa brokered a deal with a pharmaceutical company to slash the price by half.
Webinar on implementing an injectable-free regimen for drug-resistant TB - materials now available online (post)
Treatment Action Group (TAG), the Global TB Community Advisory Board (TB CAB), the Drug-Resistant TB Treatment Scale-up Action Team (DR-TB STAT) and TB Proof hosted a webinar on 16 August 2018 on implementing an injectable-free regimen for drug-resistant TB.
SimpliciTB clinical trial launched with first patients in Tbilisi, Georgia (post)
NEW YORK, NY (August 28, 2018)—TB Alliance has initiated a pivotal clinical trial, SimpliciTB (pronounced: sim-plis-i-tee-bee), that will evaluate whether a new four-drug regimen can treat most types of tuberculosis (TB) including multidrug-resistant TB (MDR-TB) more quickly and effectively than currently-available treatments. The first patients have been enrolled at the National Center for Tuberculosis and Lung Disease in Tbilisi, Georgia. SimpliciTB is expected to enroll 450 people with TB, including up to 150 with MDR-TB* across at least 26 centers in 10 countries in Africa, Asia, Europe and Latin America.
Why India must discard fear, give some TB patients ‘game-changing’ drug (post)
Like South Africa, India should immediately make available the tuberculosis (TB) drug bedaquiline – till now used as a drug of last resort – to nearly 147,000 Indians with a multidrug-resistant version of the disease, a leading South African TB-HIV researcher told IndiaSpend.
Page 52 of 117 · Total posts: 0
←First 51 52 53 Last→